You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Oral human papillomavirus infection

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Clinical Implications of HPV Infection in Male IBD Patients

Not yet recruiting
  • HPV Infection
  • +2 more
  • Anal pap smear and oral swab for cytology and HPV testing
  • Barcelona, Spain
    Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sa
Jun 26, 2023

Probiotic, Human Papillomavirus Infection, Pap Smear, Microbiome Trial in Kaohsiung (probiotic:Lactobacillus crispatus)

Recruiting
  • Probiotic, Human Papillomavirus Infection, Pap Smear, Microbiome
  • probiotic:Lactobacillus crispatus
  • Kaohsiung, Taiwan
    Kaohsiung Chang Gung Memorial Hospital
Aug 14, 2023

HPV Infection, Sexually Transmitted Infections and Anal

Not yet recruiting
  • Human Papillomavirus Infection
  • +2 more
    • (no location specified)
    Aug 1, 2023

    Human Papillomavirus-Related Cervical Carcinoma Trial in France (Agreement between oral and cervical HPV infection)

    Active, not recruiting
    • Human Papillomavirus-Related Cervical Carcinoma
    • Agreement between oral and cervical HPV infection
    • Belfort, France
    • +3 more
    Mar 29, 2022

    Human Papilloma Virus Trial in Montreal (Mouthwash gargling)

    Not yet recruiting
    • Human Papilloma Virus
    • Mouthwash gargling
    • Montreal, Quebec, Canada
      McGill University
    Feb 16, 2023

    Papilloma Viral Infection, CIN1, LSIL, Low Grade Squamous Intraepithelial Lesion Trial in Madrid (Glizigen, Placebo)

    Recruiting
    • Papilloma Viral Infection
    • +2 more
    • Glizigen
    • Placebo
    • Madrid, Spain
    • +3 more
    Jun 27, 2023

    Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection Trial in New Orleans (Human papillomavirus

    Not yet recruiting
    • Papillomavirus Vaccines
    • +6 more
    • Human papillomavirus 9-valent vaccine, recombinant
    • New Orleans, Louisiana
      University Medical Center New Orleans
    Mar 3, 2022

    HPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection, HPV Infection Trial in São Paulo, Cuernavaca, San Juan (9

    Recruiting
    • HPV Positive Oropharyngeal Squamous Cell Carcinoma
    • +2 more
    • 9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)
    • Saline Placebo
    • São Paulo, Brazil
    • +2 more
    Mar 25, 2022

    Serum Galectin-3 as a Marker of Human Papillomavirus Infection

    Completed
    • Human Papillomavirus Infection
    • cryotherapy
    • serum Galectin-3 assay
    • Assiut, Egypt
      Assiut University
    Aug 17, 2023

    Women's Values in Managing Human Papillomavirus (HPV)

    Not yet recruiting
    • Human Papilloma Virus Infection
    • No intervention
    • (no location specified)
    Nov 6, 2023

    Human Papillomavirus in Young People Epidemiological Research 4

    Not yet recruiting
    • Human Papillomavirus Infection
    • +6 more
      • (no location specified)
      Oct 17, 2022

      Human Papillomavirus in Young People Epidemiological Research 3

      Not yet recruiting
      • Human Papillomavirus Infection
      • +6 more
        • (no location specified)
        Oct 17, 2022

        Human Papillomavirus Infection Trial in United States (Laboratory Biomarker Analysis, Questionnaire Administration, Recombinant

        Active, not recruiting
        • Human Papillomavirus Infection
        • Laboratory Biomarker Analysis
        • +2 more
        • Birmingham, Alabama
        • +5 more
        Jan 26, 2023

        Cervical Carcinoma, Human Papillomavirus Infection Trial in Liberia (Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis

        Enrolling by invitation
        • Cervical Carcinoma
        • Human Papillomavirus Infection
        • Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
        • +3 more
        • Liberia, Guanacaste, Costa Rica
          Agencia Costarricense de Investigaciones Biomédicas - Fundación
        Aug 11, 2022

        Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV Trial

        Recruiting
        • Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III)
        • +3 more
        • Nonavalent HPV vaccine (9vHPV/Gardasil-9™).
        • L'Hospitalet De Llobregat, Catalunya, Spain
          Gynaecology Unit, Bellvitge University Hospital (HUB)
        Jan 24, 2023

        Global Burden Estimation of Human Papillomavirus (GLOBE-HPV)

        Not yet recruiting
        • HPV Infection
        • Urine Sample Collection
        • +2 more
        • Dhaka, Bangladesh
        • +7 more
        Nov 10, 2023

        Human Papillomavirus Infection Trial in Montreal (HPV vaccine, Gardasil 9, Hepatitis A vaccine)

        Active, not recruiting
        • Human Papillomavirus Infection
        • HPV vaccine, Gardasil 9
        • Hepatitis A vaccine
        • Montreal, Quebec, Canada
          McGill University - Division of Cancer Epidemiology
        Oct 20, 2022

        Human Papillomavirus Infection Trial in Nanjing (Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus

        Completed
        • Human Papillomavirus Infection
        • Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
        • Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine
        • Nanjing, Jiangsu, China
          CDC, Jiangsu Province
        Jan 12, 2023

        Oral HPV Infection in Patients Who Are Positive to the PAP-test

        Recruiting
        • HPV Infection
          • Catania, Italy
            AOU Policlinico G. Rodolico
          Jul 13, 2023

          HPV Infection Trial (Human interferon alpha 2b vaginal Effervescent capsules)

          Not yet recruiting
          • HPV Infection
          • Human interferon alpha 2b vaginal Effervescent capsules
          • (no location specified)
          May 8, 2023

          Human Papilloma Virus Infection Trial in Nanjing (Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus

          Completed
          • Human Papilloma Virus Infection
          • Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
          • Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)
          • Nanjing, Jiangsu, China
            CDC, Jiangsu Province
          Jan 12, 2023

          Standard Operating Procedures for Anti-HPV Antibody Detection in

          Completed
          • Human Papilloma Virus Infection
          • First-void urine collection
          • Blood draw
          • Wilrijk, Antwerp, Belgium
            university of Antwerp - centre for the evaluation of vaccination
          Nov 7, 2022

          Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Tumor Trial in Houston (Recombinant

          Active, not recruiting
          • Allogeneic Hematopoietic Stem Cell Transplant Recipient
          • Hematopoietic and Lymphoid Cell Neoplasm
          • Recombinant Human Papillomavirus Nonavalent Vaccine
          • Houston, Texas
            M D Anderson Cancer Center
          Jun 29, 2022

          Natural History of HPV Infection in Men: The HIM Study

          Completed
          • Human Papillomavirus
          • Cohort: 3000 men examined every 6 months for 4 years.
          • Pilot study: 150 men examined every 6 months for 4 years.
          • Tampa, Florida
            H. Lee Moffitt Cancer Center and Research Institute, Inc.
          Mar 22, 2022

          Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Hepatitis E Virus Infection Trial in Hanzhou

          Active, not recruiting
          • Human Papilloma Virus Infection Type 16
          • +2 more
          • Cecolin
          • Hecolin
          • Hanzhou, Zhejiang, China
            Zhejiang Provincial Center for Disease Control and Prevention
          Jun 8, 2022